Research & Development
Harbour BioMed IND for HBM7004 approved by China's NMPA
18 August 2026 - Global biopharmaceutical company Harbour BioMed (HKEX: 02142), which develops antibody therapeutics in immunology and oncology, said on Tuesday that China's National Medical Prod...
Hansa Biopharma reports first Australian transplant using Idefirix
18 August 2026 - Swedish immunomodulatory therapy company Hansa Biopharma AB (STO: HNSA) on Tuesday announced that the first commercial patient in Australia has received a living donor kidney transpla...
Lupin's Pitolisant Tablets receives US FDA approval
18 August 2026 - India-based global pharmaceutical company Lupin Limited (BSE: 500257; NSE: LUPIN; REUTERS: LUPIN.BO; BLOOMBERG: LPCIN) announced on Monday that it has received the final approval from...
Acurx receives FDA conditional acceptance for ibezapolstat brand name
17 August 2026 - Biopharmaceutical company Acurx Pharmaceuticals Inc (NASDAQ: ACXP) disclosed on Monday that it has received conditional FDA acceptance for CIFBEZY, the proposed proprietary name for i...
Lttl announces new telehealth site
17 August 2026 - US-based, direct-to-consumer telehealth brand Lttl reported on Friday that it has launched a new site that specialises in personalised GLP-1 weight management, longevity protocols, an...
Phanes Therapeutics' Spevatamig receives US FDA Fast Track designation in advanced and metastatic biliary tract carcinoma
17 August 2026 - Phanes Therapeutics Inc, a California-based, clinical-stage biotech company involved in innovative drug discovery and development in immuno-oncology, announced on Friday that the US F...